G-CSF Pathway Inhibition for Sickle Cell Vaso-Occlusion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sickle cell disease complications have limitations in efficacy and safety, and there is a need for improved therapies to reduce severity or development of these complications.
Innovation Solution
Administering a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling and/or activity to inhibit vaso-occlusion and vascular stasis in sickle cell disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current approved therapies (hydroxyurea, Endari, Adakveo, Oxbryta) are administered to treat sickle cell disease complications, then some therapeutic effect is achieved, but side effects and limited efficacy for different patient groups occur
Solution Approach 1:
The patent targets a specific molecular pathway (G-CSF signaling) to treat sickle cell disease complications. By changing the therapeutic parameter from general symptomatic management to specific molecular pathway inhibition, the treatment achieves better efficacy with potentially fewer side effects. The compound selectively inhibits G-CSF signaling to reduce vaso-occlusion and vascular stasis without the broad side effects of current therapies.
2Adaptability or versatility
If current approved therapies are administered to reduce vaso-occlusion and pain crises, then some improvement is achieved, but availability restrictions and limited efficacy for different patient groups persist
Solution Approach 1:
The G-CSF signaling inhibition approach targets a fundamental pathological mechanism (vaso-occlusion and vascular stasis) that is common across different types of sickle cell disease and patient groups. This universal mechanism targeting makes the therapy potentially applicable to all patients with sickle cell disease regardless of their specific genotype or disease severity, overcoming the limited efficacy of current therapies for different patient groups.
Data Source
AI summary
The present disclosure relates to methods for treating or preventing or delaying progression or reducing or inhibiting or hindering development of a complication associated with sickle cell disease in a subject suffering from sickle cell disease, the method comprising administering to the subject a compound that inhibits granulocyte colony stimulating factor (G-CSF) signaling and/or G-CSF activity.